Last reviewed · How we verify
NCT02335827: IRE
Irreversible Electroporation(IRE) For Unresectable Renal Tumors
NA trial testing irreversible electroporation in Renal Tumor in 15 participants. Completed in 1 January 2021.
20 May 2020
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 January 2015 |
| Primary completion | 20 May 2020 |
| Estimated completion | 1 January 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- irreversible electroporation
Conditions studied
- Renal Tumor — all drugs for Renal Tumor →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 18 to 80, any sex, with Renal Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation (IRE) for unresectable renal tumors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Application of Pulsed Electric Fields to Cancer Therapy.
Nuccitelli R. · · 2019 · cited 39× · PMID 34471806 · DOI 10.1089/bioe.2018.0001 -
Pulsed electric fields: a sharp sword in the battle against cancers.
Zhang L, Dong S, Teng F, Wang Y, et al · · 2025 · PMID 41357174 · DOI 10.3389/fimmu.2025.1682539
Verify or expand the search:
- PubMed search for NCT02335827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of irreversible electroporation
Trials testing the same drug.
- NCT02981719 — Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer · NA · completed
Other recruiting trials for Renal Tumor
Currently open trials in the same condition.
- NCT06076538 — PET/MR for Characterization of Renal Masses (RMs) · recruiting
- NCT05696444 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) · NA · active not recruiting
- NCT03810651 — Pencil Beam Scanning in Patients With Renal Tumors · EARLY_PHASE1 · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02335827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02335827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing